The stocks of NVCR have been given a rating of hold by around eleven different analysts who have been covering the stocks. One of the investment analysts has already issued the rating of sell, while four others have issued the company with a rating of hold. Four other analysts gave the company a rating of buy. The average price target of the company over the year has been set at $195.71.
The Stock Commentary of NVCR
There have been quite a few research equities that have commented on the stocks of NVCR. Piper Sandler has already increased the price target of the company from $140 to $225 with a rating of overweight in a 25th January research report. Truist Securities has also increased the price target of the company from $132 to $142 in a 19th April research report.
Wells Fargo & Company has also increased the price target from $135 to $215 with a rating of equal weight in a 13th April research note. Zacks has decided to elevate the rating from sell to hold in a 17th April research report. In the end, Mizuho Securities came ahead to increase the price target of the company from $175 to $242 with a rating of buy in a 20th April research note.
The stocks of NVCR traded on Monday at $207.63. The market cap for the firm is $21.26 billion, with a PE ratio of around 1,092.85, and a 1.29 beta. The year low of the company has been set at $55.40, with a year high of $218.09. The moving average price of the company over a period of 50 days is $145.61, with the moving average price over 200 days is $150.57.
NVCR put up its quarterly report on the 25th of February. The provider of medical equipment had an EPS of $0.04 for this quarter, which was slightly less than the consensus estimate of $0.13. The revenue generated by the company over the period was $144 million, which was more than the consensus estimate of $143.49 million. The return on equity for the company is 7.40%, with a 4.26% net margin.